GLP-1s are linked to a broad range of adverse events — largely gastrointestinal, metabolic, and psychological — across ...

GLP-1 receptor agonist use may be associated with a modest increase in erectile dysfunction (ED) risk in men with type 2 ...

Those prescribed a GLP-1 RA had a significantly increased risk for new chronic cough compared with those prescribed any non-GLP-1 RA second-line medication, DPP-4 inhibitor, or sulfonylurea in a ...

Adults with type 2 diabetes and overweight or obesity who use a GLP-1 receptor agonist have similar risk for kidney cancer as ...

Introduction India’s T2D population carries a substantial burden-nearly two-thirds of individuals with T2D are overweight or obese, indicating a significant cardio-metabolic risk burden (1).

GLP-1 receptor agonists have been linked to a reduced risk for epilepsy in patients with type 2 diabetes. Results of an observational study showed that patients taking GLP-1s were 16% less likely to ...

New data reveal key differences in antihyperglycaemic agents safety for older adults with Type 2 diabetes. Learn more.

Please provide your email address to receive an email when new articles are posted on . GLP-1s may be the most cardioprotective glucose-lowering agents for patients with type 2 diabetes. Their effect ...

Patients with type 2 diabetes and inflammatory arthritis who received GLP-1 RAs had lower rates of hypoglycemia, serious infections, and acute kidney injury vs those receiving SGLT2 inhibitors.